Track topics on Twitter Track topics that are important to you
Phoenix, Aug. 04, 2016 (GLOBE NEWSWIRE) -- BioNovelus, Inc. (PINKSHEETS: ONOV) is proud to announce that its green fungicide CR-10 has now been officially introduced to National Coffee Trade Associations, major coffee growers and cooperatives, and key distributors of agrochemicals in Mexico, Costa Rica, and Guatemala. Concurrently, the registration process for CR-10 in each of these countries have begun. Upon regulatory approval in each country, the commercial distribution and selling of CR-10 will commence.
Two critically vital pilot tests were launched in July in Guatemala by two of its leading coffee producers. Separately, another significant test is being performed in both the laboratory and in the fields by the Guatemalan Coffee Trade Association, Anacafé. If conclusively proven successful, CR-10 will receive Anacafé’s imperative and vital seal of approval.
Coffee is the main source of revenue for Guatemala. Experts agree that coffee rust fungus is a devastating disease, since 2012, causing an unrelenting loss of production and resulting in a deleterious economic impact on the country and its citizens.
BioNovelus’ 2nd 10Q, quarterly financial report, will be available on the OTC and BioNovelus websites on August 5, 2016.
Jean Ekobo, CEO, will host a conference call on Monday August 8, 2016, at 4:00PM PST, updating recent activities and answering shareholders’ questions. Please send questions in advance to firstname.lastname@example.org.
Conference call dial: +1 712-432-3100
Access code: 846419
If you miss the live conference call, it will be posted on BioNovelus website.
About BioNovelus Inc.
BioNovelus, Inc. (PINKSHEETS: ONOV) is a biotech company that honors the environment with an innovative, cost effective and disruptive technology-based solution to the problems of safety and cleanliness regarding food production and water supply.
BioNovelus’ primary target market is the $100 Billion, annually, worldwide, coffee industry. Coffee Rust or "Roya" (Hemileia vastatrix), is a devastating fungus attacking the Arabica plant, currently, the coffee industry’s greatest threat. So far, billions of dollars and hundreds of thousands of industry jobs have been lost throughout Central America since 2012.
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2015 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.
Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company's control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
For additional information: http://bionovelus.com Please contact: Nathalie Ekobo, Marketing & Communications Director BioNovelus, Inc. Skype: bionovelus.inc +1 602-888-3424 NEkobo@BioNovelus.comNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...